Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are scheduled to receive a specialised type of targeted radiation therapy (called stereotactic body radiotherapy) through the Thoracic Radiation Oncology Service at MD Anderson.
Who may not be able to join:
- People who have a medical reason that prevents them from using a CPAP device (a mask-based breathing machine often used during sleep).
- People who have not signed the consent form specific to this study.
- People who are unable or unwilling to cooperate with the study procedures.
- People who have a reduced level of consciousness.
- People who have injuries or burns to the face.
- People who have had surgery on the face, food pipe (oesophagus), stomach, or sinuses within the past 3 months.
- People who have a lung condition called idiopathic pulmonary fibrosis (IPF) recorded in their medical history.
- Adults who are unable to give their own consent to participate.
- People who are under 18 years of age.
- People who are pregnant.
- People who are currently imprisoned.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Julianne M Pollard, M.D. Anderson Cancer Center
Phone: 713-563-2591
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Estimation of decrease in tumor motion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.